Objective To analyze the application effect of photonrejuvenation in facial telangiectasia and its influence on pigmentation and erythema regression time. Methods A total of 132 patients with facial telangiectasia admitted to our hospital from September 2022 to September 2024 were selected as the research subjects. According to the random number table method, they were divided into group A (n =66) and group B (n =66). Group A was given conventional drug treatment, and group B was given photonrejuvenation treatment on the basis of conventional drug treatment. The clinical efficacy, pigmentation and erythema regression time, skin lesion symptom score, adverse reactions and quality of life were compared between the two groups. Results The total clinical effective rate of group B (96.97%) was higher than that of group A (84.85%) (P <0.05). The pigmentation regression time and erythema regression time of group B were shorter than those of group A (P <0.05). The skin lesion symptom score of group B after treatment was lower than that of group A (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P >0.05). The DLQI score of group B after treatment was lower than that of group A (P <0.05). Conclusion Photonrejuvenation can effectively improve the clinical symptoms of patients with facial telangiectasia, promote the regression of pigmentation and erythema, improve their quality of life, and has a low incidence of adverse reactions and high safety.